New trial
Spotlight
Phase 1 MBRT: tungsten‐slit collimator enables spatially fractionated minibeam radiation therapy
- Trial ID
- NCT07062003 on ClinicalTrials.gov
- Cancer type
- Sarcoma (USTS)
- Stage of research
- First-in-human
- Published in
- New in Oncology - Aug 1, 2025
Investigating the safety and optimal dose of MBRT at Mayo Clinic, this study tests minibeam radiation—delivered via a tungsten slit collimator that creates alternating peak and valley dose regions—in patients with recurrent or metastatic skin and superficial soft tissue tumors using CT simulation and biospecimen collection.
More in sarcoma and GIST
-
Trial result · Oct 22, 2026 · NCT04514484
Nivolumab + cabozantinib shows feasible safety and prolonged disease stabilization in a small HIV-positive solid-tumor cohort -
New trial · Oct 8, 2026 · NCT07781891
Phase 2 LX-101 IGF-1R–targeted methotrexate conjugate in R/R Ewing sarcoma/DSRCT -
Trial result · Sep 10, 2026 · NCT03069469
Vimseltinib (CSF1R switch-control inhibitor) delivers 64% ORR in surgery-ineligible TGCT, including post–CSF1/CSF1R-treated patients -
New trial · Aug 13, 2026 · NCT07725380
Phase 1/2 domatinostat class I HDAC inhibitor + sirolimus mTOR inhibitor in R/R sarcoma/osteosarcoma. -
Trial result · Aug 6, 2026 · NCT05218499
Brigimadlin (MDM2–p53 antagonist) Misses PFS Endpoint vs Doxorubicin in 1L DDLPS, Despite Higher ORR